Court Narrows Moderna Defenses in Arbutus Patent Dispute
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Arbutus Biopharma ( (ABUS) ).
On February 17, 2026, the U.S. District Court for the District of Delaware issued a memorandum and order in the patent infringement case brought by Arbutus Biopharma and its licensee Genevant Sciences against Moderna over the mRNA-1273 COVID-19 vaccine. The court held that Moderna is estopped from re-litigating many obviousness challenges to Arbutus’s patents that it had already raised or could have raised in earlier inter partes review proceedings, narrowing Moderna’s defenses and reinforcing the strength of Arbutus’s patent estate.
The court also found that Moderna lacks sufficient evidence to support its derivation defense but allowed its enablement defense to proceed to a jury based on admissible expert opinions that create factual disputes. These rulings shape the contours of the upcoming trial, limiting Moderna’s ability to attack the validity of key Arbutus patents while preserving a central technical challenge, and they underscore the legal and commercial stakes surrounding lipid nanoparticle technologies used in mRNA vaccines.
The most recent analyst rating on (ABUS) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
The score is primarily constrained by weak financial performance (large losses, negative margins, declining revenue, and negative operating/free cash flow). Technicals are also soft with the price below key short- and mid-term moving averages and weak momentum indicators. Valuation is less supportive due to a negative P/E, and corporate events add uncertainty due to litigation and patent-related risks.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma is a biotechnology company focused on nucleic acid-lipid nanoparticle technologies and related lipid vesicle formulations used to deliver messenger RNA and other nucleic acids into human cells. Its intellectual property underpins drug delivery systems that are critical for mRNA-based therapeutics and vaccines, positioning the company as an important player in the RNA delivery segment of the biopharmaceutical industry.
Average Trading Volume: 1,552,458
Technical Sentiment Signal: Buy
Current Market Cap: $794.3M
See more data about ABUS stock on TipRanks’ Stock Analysis page.
